DAFNE: authors' response to electronic letters from 5th October to 22nd October 2002. / DAFNE, Study Group; Heller , S; Speight, J; Amiel, S; Bradley, Clare; James, P; Roberts, S.

In: British Medical Journal, 29.10.2002.

Research output: Contribution to journalLetter

Published
  • Study Group DAFNE
  • S Heller
  • J Speight
  • S Amiel
  • Clare Bradley
  • P James
  • S Roberts

Abstract

The rapid responses received following the publication of the DAFNE trial reflect the controversy surrounding the current inadequate management of Type 1 diabetes. [1] While it is true that the approach is not novel (Ullman, 5th Oct; Black,6th Oct; Reed, 9th Oct; Chaufan, 12th October, Cohen, 22nd Oct), it is new to the UK. The biomedical benefits of this intensified approach had been known for some time in parts of Europe [2,3] but is was unclear whether these could be transferred to a British health care setting. furthermore, the impact on quality of life was unknown, as psychological outcomes were not measured in the early German work.
Original languageEnglish
JournalBritish Medical Journal
Publication statusPublished - 29 Oct 2002
This open access research output is licenced under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.

ID: 1417161